RxDoctor Payments Data

Storm Eagle, APRN

Family · Moore, OKNPI 1649607383

Payments from drug & device makers

$7,019in general payments, 2019–2025

Across 391 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$1K
  • AbbVie$803
  • Lilly USA, LLC$639
  • Novo Nordisk$432
  • Boehringer Ingelheim$422
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$7,012100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,019 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$85,331
Medicare patients
212
Services billed
1,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin108$103,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$95,869
OzempicSemaglutide69$79,685
FarxigaDapagliflozin Propanediol64$57,854
EliquisApixaban44$50,053
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$47,145
TrulicityDulaglutide37$46,830
MounjaroTirzepatide31$38,249
LinzessLinaclotide22$21,762
JanuviaSitagliptin Phosphate18$21,652
XareltoRivaroxaban14$17,476
MyrbetriqMirabegron14$15,986
Spiriva RespimatTiotropium Bromide13$11,374
SymbicortBudesonide/Formoterol Fumarate15$6,559
Tresiba Flextouch U-200Insulin Degludec12$6,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$422$114,838121 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,276$111,558149 claims
GSKTrelegy Ellipta$1,326$95,869102 claims
Lilly USA, LLCTrulicity, Mounjaro$639$85,07968 claims
Novo NordiskOzempic$432$79,68569 claims
PfizerEliquis$141$50,05344 claims
AbbVieLinzess$803$21,76222 claims
MerckJanuvia$12$21,65218 claims
Johnson & JohnsonXarelto$40$17,47614 claims
Astellas Pharma US IncMyrbetriq$23$15,98614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.

Other family in Moore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →